MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
| Data(s) |
10/07/2013
10/07/2013
01/09/2009
|
|---|---|
| Resumo |
The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML. Additional file 1 Expression of 250 miRNAs in resistant and responder CML patients. The data provided represent the expression of microRNA. Supported by grants from Beca Ortiz de Landázuri 2006, Departamento de Salud-Gobierno de Navarra; Fondo de Investigación Sanitaria (FIS, Spain), PI070602, PI070608, PI060003, CP07/00215 and RD06/0020; Junta de Andalucía 0386/2006 and 0004/2007; Asociación Medicina e Investigación (AMI) and "UTE project CIMA". |
| Identificador |
San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol. Cancer. 2009; 8:69 1476-4598 (Online) PMC2743636 http://hdl.handle.net/10668/1209 19723306 10.1186/1476-4598-8-69 |
| Idioma(s) |
en |
| Publicador |
BioMed Central |
| Relação |
Molecular cancer http://www.molecular-cancer.com/content/8/1/69/abstract |
| Direitos |
Acceso abierto |
| Palavras-Chave | #Antineoplásicos #Análisis de cluster #Resistencia a antineoplásicos #Leucemia mielogenosa crónica BCR-ABL positiva #MicroARN #Pirimidinas #Reacción en cadena de la polimerasa de transcriptasa inversa #Perfiles de expresión génica #Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents #Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Cluster Analysis #Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm #Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Gene Expression Profiling #Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans #Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive #Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Antisense::MicroRNAs #Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Piperazines #Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Nucleic Acid Amplification Techniques::Polymerase Chain Reaction::Reverse Transcriptase Polymerase Chain Reaction |
| Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/published Artículo |
